Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who are 60 to 90 years of age may be eligible to participate~* Bone mineral density (BMD) T-Score at hip or spine must be less than -2.5~Exclusion Criteria:~* BMD T-Score at the hip or the spine of less than -4.0~* Patients with any severe or more than two moderate vertebral fractures on spinal x-ray at entry

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered subcutaneously once every 6 months for 3 years.
- Denosumab 60 mg Q6M (Type: EXPERIMENTAL): Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).